Introduce of REGN-COV2 into Subcu, Perc Approach, New Tech 6

This code describes the administration of REGN-COV2, a specific monoclonal antibody therapy, directly into the subcutaneous tissue. This procedure is performed using a percutaneous approach, meaning it involves puncturing the skin with a needle. It is categorized under a new technology group, indicating its recent development and unique classification.

This code is used when a patient receives REGN-COV2 via subcutaneous injection for conditions such as post-exposure prophylaxis or treatment of mild to moderate COVID-19. It is typically administered in an outpatient or inpatient setting for eligible patients who meet specific criteria for this monoclonal antibody therapy.

• Ensure documentation clearly specifies "REGN-COV2" as the substance introduced.
• Verify the route of administration is explicitly documented as "subcutaneous" and the approach as "percutaneous."
• Confirm the procedure was performed for an inpatient encounter to use an ICD-10-PCS code.